BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CLC bio Continues Success With a 30 Percent Growth in Software Sales and over 500 New Organizations as Customers in 2012


2/12/2013 9:58:59 AM

AARHUS, Denmark--(BUSINESS WIRE)--Today, the world’s leading bioinformatics software company, CLC bio, is pleased to announce a continued positive development in 2012 with a 30% increase in both software sales and employees, and more than a 30% rise in new organizations as customers. “In many ways, 2012 featured significant milestones for us as a company. We now have more than 100 employees around the world, which together with our market reach makes us the largest bioinformatics company focusing on next generation sequencing. We also added more than 500 new unique organizations to our customer list, surpassing 2000 in total", states CEO at CLC bio, Thomas Knudsen, and continues, "In September we acquired our first company, Molegro. This was a very positive process and we’re looking forward to bringing even more drug discovery software to the market in the future. Last but not least, we’re profitable and cash-flow positive for the third year in a row, enabling further growth in the years to come."

Read at BioSpace.com

CLC bio
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES